Javier Jiménez-Díaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Javier Jiménez-Díaz has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
Felipe Higuera‐Sobrino
Arrhythmia Unit, Cardiology Department, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain
2 shared publications- Adriano Nunes Kochi
Electrophysiology Department Hospital Mãe de Deus Porto Alegre Brazil
1 shared publication Alba Cruz
Cardiovascular Institute, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid (V.C.-G., J.J.G.-F., D.C.-C., R.S.-A., A.C., J.G.Q., J.P.-V., N.P.-C., D.F.-R.).
1 shared publication- Alba García-Escolano
Novel Arrhythmogenic Mechanisms Program, Centro Nacional de Investigaciones Cardiovasculares (CNIC) (J.D.-D., G.L.R., M.S.-P., M.M.-B., A.G.-E., A.R.-P., A.R.-R., J.G.Q., S.P., D.F.-R.).
1 shared publication Alba Ramos-Prada
Novel Arrhythmogenic Mechanisms Program, Centro Nacional de Investigaciones Cardiovasculares (CNIC) (J.D.-D., G.L.R., M.S.-P., M.M.-B., A.G.-E., A.R.-P., A.R.-R., J.G.Q., S.P., D.F.-R.).
1 shared publication- Alberto Barrera-Cordero
Department of Cardiology, Hospital Universitario Virgen de la Victoria, Málaga (A.B.).
1 shared publication
Latest Publications
- Open Access
- 20 November 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
Dynamic Risk Assessment of Severe Ventricular Arrhythmia in Patients With Implantable Defibrillators and Reduced Left Ventricular Ejection Fraction
BACKGROUND: Device shocks are associated with an adverse prognosis in patients with implantable cardioverter-defibrillators. This study aimed to develop and validate a predictive model based on dynamic changes in intracardiac electrograms to assess the risk of polymorphic ventricular tachycardia or ventricular fibrillation (VF) events in patients with implantable cardioverter-defibrillators and heart failure with reduced ejection fraction (HFrEF). METHODS: Experimental studies were conducted in pigs with HFrEF (N=8) to characterize intracardiac electrogram and surface ECG changes during HF decompensation. Sham-operated animals (N=6) were used as controls. In patients, the study used data from 2 independent cohorts of patients with ICDs. The first cohort included 5089 patients from 50 centers (199 218 tracings), leveraging electrical parameters associated with HFrEF decompensation in the experimental model to train and internally validate a dynamic convolutional neural network model for polymorphic ventricular tachycardia/VF prediction. External validation was performed in a second cohort of 2040 patients from 7 centers (369 845 tracings). RESULTS: In pigs, HFrEF decompensation was associated with QRS prolongation on surface ECG tracings and reduced bipolar R-wave amplitude in intracardiac electrograms. Hemodynamic and electrical alterations of HFrEF decompensation significantly increased the risk of inducible VF episodes compared with sham-operated controls (87.5% versus 0%, respectively; P <0.001). In a clinical setting, a convolutional neural network–derived model predicted first VF or polymorphic ventricular tachycardia events by analyzing temporal patterns of R-wave amplitude, QRS duration, and premature ventricular complex burden. This approach yielded areas under the receiver operating characteristic curve of 0.787 (0.753–0.817) for the training cohort and 0.725 (0.709–0.739) for the external validation cohort. Dynamic risk prediction using the convolutional neural network model significantly outperformed static risk assessment based on clinical variables (area under the receiver operating characteristic curve, 0.617 [0.602–0.632]). CONCLUSIONS: A convolutional neural network–derived model, grounded in the pathophysiology of HFrEF, provides dynamic risk assessment of VF or polymorphic ventricular tachycardia events in patients with implantable cardioverter-defibrillator devices.
- 20 November 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
Open AccessDynamic Risk Assessment of Severe Ventricular Arrhythmia in Patients With Implantable Defibrillators and Reduced Left Ventricular Ejection Fraction
BACKGROUND: Device shocks are associated with an adverse prognosis in patients with implantable cardioverter-defibrillators. This study aimed to develop and validate a predictive model based on dynamic changes in intracardiac electrograms to assess the risk of polymorphic ventricular tachycardia or ventricular fibrillation (VF) events in patients with implantable cardioverter-defibrillators and heart failure with reduced ejection fraction (HFrEF). METHODS: Experimental studies were conducted in pigs with HFrEF (N=8) to characterize intracardiac electrogram and surface ECG changes during HF decompensation. Sham-operated animals (N=6) were used as controls. In patients, the study used data from 2 independent cohorts of patients with ICDs. The first cohort included 5089 patients from 50 centers (199 218 tracings), leveraging electrical parameters associated with HFrEF decompensation in the experimental model to train and internally validate a dynamic convolutional neural network model for polymorphic ventricular tachycardia/VF prediction. External validation was performed in a second cohort of 2040 patients from 7 centers (369 845 tracings). RESULTS: In pigs, HFrEF decompensation was associated with QRS prolongation on surface ECG tracings and reduced bipolar R-wave amplitude in intracardiac electrograms. Hemodynamic and electrical alterations of HFrEF decompensation significantly increased the risk of inducible VF episodes compared with sham-operated controls (87.5% versus 0%, respectively; P <0.001). In a clinical setting, a convolutional neural network–derived model predicted first VF or polymorphic ventricular tachycardia events by analyzing temporal patterns of R-wave amplitude, QRS duration, and premature ventricular complex burden. This approach yielded areas under the receiver operating characteristic curve of 0.787 (0.753–0.817) for the training cohort and 0.725 (0.709–0.739) for the external validation cohort. Dynamic risk prediction using the convolutional neural network model significantly outperformed static risk assessment based on clinical variables (area under the receiver operating characteristic curve, 0.617 [0.602–0.632]). CONCLUSIONS: A convolutional neural network–derived model, grounded in the pathophysiology of HFrEF, provides dynamic risk assessment of VF or polymorphic ventricular tachycardia events in patients with implantable cardioverter-defibrillator devices.
- Open Access
- 29 October 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (11)
Ultrasound-guided vs. fluoro-guided axillary venous access for cardiac implantable electronic devices: a patient-based meta-analysis
Aims: The use of ultrasound (US)-guided venous puncture for cardiac pacing/defibrillation lead placement may minimize the risk of periprocedural complications and radiation exposure. However, none of the published studies have been sufficiently powered to recommend this approach as the standard of care. We compare the safety and efficacy of ultrasound-guided axillary venous puncture (US-AVP) vs. fluoroscopy-guided access for cardiac implantable electronic devices (CIEDs) by performing an individual patient data meta-analysis based on previously published studies. Methods and results: We conducted a thorough literature search encompassing longitudinal investigations (five randomized and one prospective studies) reporting data on X-ray-guided and US-AVP for CIED procedures. The primary endpoint was to compare the safety of the two techniques. Secondary endpoints included the success rate of each technique, the necessity of switching to alternative methods, the time needed to obtain venous access, X-ray exposure, and the occurrence of periprocedural complications. Six longitudinal eligible studies were identified including 700 patients (mean age 74.9 ± 12.1 years, 68.4% males). The two approaches for venous cannulation showed a similar success rate. The use of an X-ray-guided approach significantly increased the risk of inadvertent arterial punctures (OR: 2.15, 95% CI: 2.10–2.21, P = 0.003), after adjustment for potential confounders. Conversely, a US-AVP approach reduces time to vascular access, radiation exposure, and the number of attempts to vascular access. Conclusion: The US-AVP enhances safety by reducing radiation exposure and time to vascular access while maintaining a low rate of major complications compared to the X-ray-guided approach. Clinical trial registration: PROSPERO identifier: CRD42024539623.
- 29 October 2024
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 26 (11)
Open AccessUltrasound-guided vs. fluoro-guided axillary venous access for cardiac implantable electronic devices: a patient-based meta-analysis
Aims: The use of ultrasound (US)-guided venous puncture for cardiac pacing/defibrillation lead placement may minimize the risk of periprocedural complications and radiation exposure. However, none of the published studies have been sufficiently powered to recommend this approach as the standard of care. We compare the safety and efficacy of ultrasound-guided axillary venous puncture (US-AVP) vs. fluoroscopy-guided access for cardiac implantable electronic devices (CIEDs) by performing an individual patient data meta-analysis based on previously published studies. Methods and results: We conducted a thorough literature search encompassing longitudinal investigations (five randomized and one prospective studies) reporting data on X-ray-guided and US-AVP for CIED procedures. The primary endpoint was to compare the safety of the two techniques. Secondary endpoints included the success rate of each technique, the necessity of switching to alternative methods, the time needed to obtain venous access, X-ray exposure, and the occurrence of periprocedural complications. Six longitudinal eligible studies were identified including 700 patients (mean age 74.9 ± 12.1 years, 68.4% males). The two approaches for venous cannulation showed a similar success rate. The use of an X-ray-guided approach significantly increased the risk of inadvertent arterial punctures (OR: 2.15, 95% CI: 2.10–2.21, P = 0.003), after adjustment for potential confounders. Conversely, a US-AVP approach reduces time to vascular access, radiation exposure, and the number of attempts to vascular access. Conclusion: The US-AVP enhances safety by reducing radiation exposure and time to vascular access while maintaining a low rate of major complications compared to the X-ray-guided approach. Clinical trial registration: PROSPERO identifier: CRD42024539623.
- Open Access
- 20 November 2023
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 29 (1) , e13095
Usefulness of risk scores and predictors of atrial fibrillation recurrence after elective electrical cardioversion
Introduction: Electrical cardioversion (ECV) is a frequently used procedure for restoring sinus rhythm in atrial fibrillation (AF); however, the rate of recurrence is high. The identification of patients at high risk of recurrence could influence the decision‐making process. The present study evaluates the predictive value of risk scores in atrial fibrillation recurrence after elective electrical cardioversion.Methods: Unicentric, observational, and prospective study of adult patients who have undergone an elective ECV as rhythm control strategy between July 2017 and September 2022.Results: From the 283 analyzed patients (mean age 63.95 ± 10.76212, 74.9% male); 99 had paroxysmal AF (35%) and 159 (59%) presented AF recurrence during a follow‐up of 6 months. In patients with post‐ECV AF recurrence, the period of time from diagnosis until the performance of the procedure was longer (393 ± 891 vs. 195 ± 527, p = .02). No paroxysmal AF (71.3% vs. 57.8%, p = .02) and LA dilatation with >40 mL/m2 (35.9% vs. 23.3%, p = .02) volumes were more frequent within these patients. AF recurrence was more frequent in patients who had previous ECV (HR = 1.32; 95% CI: 1.12–2.35; p = .01) and more than 1 shock to recover sinus rhythm (HR = 1.62; 95% CI: 1.07–1.63; p = .01). The SLAC, ALARMEc, ATLAS, and CAAP‐AF scores were statistically significant, although with a moderate predictive capacity for post‐ECV recurrence.Conclusions: Risk scores analyzed showed a modest value predicting AF recurrence after ECV. Previous ECV, and greater difficulty in restoring SR were independent predictors of recurrence.
- 20 November 2023
- Published by Wiley in Annals of Noninvasive Electrocardiology
- Vol. 29 (1) , e13095
Open AccessUsefulness of risk scores and predictors of atrial fibrillation recurrence after elective electrical cardioversion
Introduction: Electrical cardioversion (ECV) is a frequently used procedure for restoring sinus rhythm in atrial fibrillation (AF); however, the rate of recurrence is high. The identification of patients at high risk of recurrence could influence the decision‐making process. The present study evaluates the predictive value of risk scores in atrial fibrillation recurrence after elective electrical cardioversion.Methods: Unicentric, observational, and prospective study of adult patients who have undergone an elective ECV as rhythm control strategy between July 2017 and September 2022.Results: From the 283 analyzed patients (mean age 63.95 ± 10.76212, 74.9% male); 99 had paroxysmal AF (35%) and 159 (59%) presented AF recurrence during a follow‐up of 6 months. In patients with post‐ECV AF recurrence, the period of time from diagnosis until the performance of the procedure was longer (393 ± 891 vs. 195 ± 527, p = .02). No paroxysmal AF (71.3% vs. 57.8%, p = .02) and LA dilatation with >40 mL/m2 (35.9% vs. 23.3%, p = .02) volumes were more frequent within these patients. AF recurrence was more frequent in patients who had previous ECV (HR = 1.32; 95% CI: 1.12–2.35; p = .01) and more than 1 shock to recover sinus rhythm (HR = 1.62; 95% CI: 1.07–1.63; p = .01). The SLAC, ALARMEc, ATLAS, and CAAP‐AF scores were statistically significant, although with a moderate predictive capacity for post‐ECV recurrence.Conclusions: Risk scores analyzed showed a modest value predicting AF recurrence after ECV. Previous ECV, and greater difficulty in restoring SR were independent predictors of recurrence.
- 21 August 2019
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (10) , 2184
Response to Letter to Editor by Creta A et al
- 21 August 2019
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (10) , 2184
Response to Letter to Editor by Creta A et al
- 16 July 2019
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (9) , 1588-1593
Fluoroscopy‐guided axillary vein access vs cephalic vein access in pacemaker and defibrillator implantation: Randomized clinical trial of efficacy and safety
Introduction: The most widespread venous sites of access for implantation intravenous implantable cardiac electronic device (CIED) are the cephalic and subclavian vein. Fluoroscopy‐guided axillary venous access is an alternative, but efficacy and safety have not been studied under equal conditions. The aim of the present study is to compare the efficacy and safety of fluoroscopy‐guided axillary vs cephalic vein access in CIED implant.Methods and Results: Two hundred and forty patients were randomized to receive CIED implantation by the fluoroscopy‐guided axillary vein access vs cephalic vein access. The implantation success, the procedure times and the complications were recorded. A comparison of the results of operators was made. The success rate of the randomized venous access was superior in the axillary group than in cephalic (98.3% vs 76.7%, P < .001). Time to access (6.8 ± 3.1 minute vs 13.1 ± 5.8 minutes, P < .001) and implantation duration was significantly shorter in the axillary group than in the cephalic group (42.3 ± 11.6 minutes vs 50.5 ± 13.3 minutes, P < .001). There was no difference in the incidence of complication and inter‐operator success rate, complications rate and time to access.Conclusion: The fluoroscopy‐guided axillary venous access is safe and has a better success rate and faster execution time compared with the cephalic vein access. When the results were compared among the study operators, neither in the axillary nor in the cephalic group there were differences in the success rate, the complication rate, and the time to access.Trial Registration: www.clinicaltrials.gov, NCT03860090
- 16 July 2019
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (9) , 1588-1593
Fluoroscopy‐guided axillary vein access vs cephalic vein access in pacemaker and defibrillator implantation: Randomized clinical trial of efficacy and safety
Introduction: The most widespread venous sites of access for implantation intravenous implantable cardiac electronic device (CIED) are the cephalic and subclavian vein. Fluoroscopy‐guided axillary venous access is an alternative, but efficacy and safety have not been studied under equal conditions. The aim of the present study is to compare the efficacy and safety of fluoroscopy‐guided axillary vs cephalic vein access in CIED implant.Methods and Results: Two hundred and forty patients were randomized to receive CIED implantation by the fluoroscopy‐guided axillary vein access vs cephalic vein access. The implantation success, the procedure times and the complications were recorded. A comparison of the results of operators was made. The success rate of the randomized venous access was superior in the axillary group than in cephalic (98.3% vs 76.7%, P < .001). Time to access (6.8 ± 3.1 minute vs 13.1 ± 5.8 minutes, P < .001) and implantation duration was significantly shorter in the axillary group than in the cephalic group (42.3 ± 11.6 minutes vs 50.5 ± 13.3 minutes, P < .001). There was no difference in the incidence of complication and inter‐operator success rate, complications rate and time to access.Conclusion: The fluoroscopy‐guided axillary venous access is safe and has a better success rate and faster execution time compared with the cephalic vein access. When the results were compared among the study operators, neither in the axillary nor in the cephalic group there were differences in the success rate, the complication rate, and the time to access.Trial Registration: www.clinicaltrials.gov, NCT03860090